Novartis: FDA OKs Tafinlar + Mekinist For Solid Tumors With BRAF V600E Mutation

Swiss drug major Novartis AG (NVS) announced Thursday that the US Food and Drug Administration or FDA granted accelerated approval for Tafinlar (dabrafenib) + Mekinist (trametinib) to treat unresectable or metastatic solid tumors with BRAF V600E mutation.